Scientists Use 3-D Printer to Speed Human Embryonic Stem Cell Research
By Larry Greenemeier,
Scientific American
| 02. 04. 2013
Every week, it seems, there’s a new breakthrough in 3-D printing that promises us the ability to (eventually) fabricate some new thing in one of those glass-walled wonder boxes. Such things have included everything from
spare parts for the International Space Station above to the
beef on our dinner plates to the
organs inside our bodies. Although this last idea of fabricating body parts may seem the most fanciful, a team of scientists is reporting a breakthrough in 3-D printing using human embryonic stem cells that could purportedly lead to life-like bioengineered tissue and, eventually, artificial organs tailor-made for specific patients.
Researchers have been able to engineer tissue samples in the past by combining artificial scaffold-like structures and animal cells. Depositing human embryonic stem cells in cultures using a 3-D printer offers some advantages. In particular, the cells can be positioned in droplets of uniform size cheaper, faster and more easily than using manual methods. This uniformity is important for researchers trying to generate specific cell types.
Whereas human embryonic stem cells have proved too fragile to print in...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...